Free Trial
NASDAQ:KDNY

Chinook Therapeutics (KDNY) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$40.39
$40.39
50-Day Range
$38.66
$40.39
52-Week Range
$18.34
$40.51
Volume
N/A
Average Volume
1.19 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.00
KDNY stock logo

About Chinook Therapeutics Stock (NASDAQ:KDNY)

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.

KDNY Stock News Headlines

This is the type of environment we pray for…
There is a situation in the market right now that requires your immediate attention. It involves a company that has $9 billion in cash, only $500,000 in debt, and a market cap of around $8 billion. This may not mean much to you right now.
Chinook Elementary
Chinook Therapeutics, Inc. (KDNY)
Expert Ratings for Chinook Therapeutics
This is the type of environment we pray for…
There is a situation in the market right now that requires your immediate attention. It involves a company that has $9 billion in cash, only $500,000 in debt, and a market cap of around $8 billion. This may not mean much to you right now.
Chinook Therapeutics (NASDAQ: KDNY)
Why Are Chinook Therapeutics Shares Trading Higher Today
See More Headlines
Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2023
Today
7/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:KDNY
Fax
N/A
Employees
214
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$41.00
High Stock Price Target
$42.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+1.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-187,870,000.00
Net Margins
-4,199.93%
Pretax Margin
-4,115.56%

Debt

Sales & Book Value

Annual Sales
$6.13 million
Book Value
$6.91 per share

Miscellaneous

Free Float
59,749,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
0.34
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives


KDNY Stock Analysis - Frequently Asked Questions

How were Chinook Therapeutics' earnings last quarter?

Chinook Therapeutics, Inc. (NASDAQ:KDNY) announced its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by $0.03. The business's revenue was down 32.2% on a year-over-year basis.

What other stocks do shareholders of Chinook Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).

This page (NASDAQ:KDNY) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners